drugset / Trial / NCT07086222
Efficacy and Safety of NVX-CoV2705
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days.
Timeline
- Start
- 2025-11-20
- Primary completion
- 2026-11-18
- Completion
- 2026-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NVX-CoV2705 | Vaccine | 5 ug | Intramuscular |
| Subject | NVX-CoV2705 | Vaccine | 50 ug | Intramuscular |